C. perfringens Disease Detection via Excrement Marker Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting C. perfringens-induced diseases in animals are invasive, time-consuming, and impractical for large-scale monitoring, especially for subclinical forms, which complicates early detection and management in animal populations.
Innovation Solution
A method involving the collection of sample material at consecutive points in time to determine the ratio of specific polynucleotide markers (netB and cpa) in animal excrements, where an increase in this ratio indicates the presence of avian necrotic enteritis, allowing for non-invasive, fast, and reliable detection of C. perfringens-induced diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional invasive detection methods are used to detect C. perfringens-induced diseases, then detection reliability is improved, but ease of operation and productivity deteriorate due to time-consuming procedures and impracticality for large-scale monitoring
Solution Approach 1:
The invention extracts and analyzes specific polynucleotide markers (netB and cpa genes) from animal excrements to detect C. perfringens-induced diseases. This extraction approach enables non-invasive detection while maintaining reliability by focusing on disease-specific genetic markers rather than using complex invasive procedures
Solution Approach 2:
The invention replaces traditional mechanical/invasive detection methods with molecular biology techniques (PCR amplification and sequencing) that analyze nucleic acids in excrements. This substitution eliminates the need for invasive sampling while improving ease of operation and enabling large-scale monitoring
2Reliability
If traditional invasive detection methods are used to detect C. perfringens-induced diseases, then detection reliability is improved, but productivity deteriorates due to time-consuming procedures
Solution Approach 1:
The invention extracts specific polynucleotide markers from excrements and uses PCR amplification to rapidly generate detectable quantities of target DNA. This extraction and amplification approach maintains detection reliability while dramatically reducing detection time compared to traditional methods
Solution Approach 2:
The invention performs preliminary PCR amplification of target polynucleotide markers before detection, which accelerates the overall detection process. This preliminary action allows for rapid identification of disease markers in large numbers of samples, improving productivity while maintaining reliability
3Measurement precision
If detection of subclinical forms is prioritized, then early detection capability is improved, but device complexity increases due to need for sensitive monitoring methods
Solution Approach 1:
The invention replaces complex clinical examination procedures with simplified molecular detection of polynucleotide markers in excrements. This substitution enables sensitive detection of subclinical forms through analysis of genetic markers while reducing device and procedural complexity
Solution Approach 2:
The invention uses PCR amplification to create copies of target polynucleotide markers from small amounts of DNA in excrements. This copying process enables sensitive detection of subclinical forms by amplifying trace amounts of disease-specific genetic material without requiring complex diagnostic equipment
4Ease of operation
If non-invasive detection method is used, then ease of operation and productivity are improved, but measurement precision may deteriorate
Solution Approach 1:
The invention extracts specific polynucleotide markers (netB and cpa genes) from excrements with high specificity. This extraction approach maintains measurement precision by targeting disease-specific genetic sequences while enabling non-invasive sampling through excrement collection
Solution Approach 2:
The invention uses molecular biology techniques (PCR and sequencing) to detect polynucleotide markers in excrements, replacing invasive sampling methods. This substitution maintains measurement precision through specific amplification of target genes while dramatically improving ease of operation through non-invasive sample collection
Data Source
AI summary
The present invention relates to a method for detecting C. perfringens induced diseases in animals, the method comprising: a) collecting sample material of a specific animal or of a specific group of animals at consecutive points in time; b) determining the amount of a first marker and a second marker contained in the sample material; and c) determining the ratio of the first marker to the second marker contained in the sample material; wherein the first marker comprises a polynucleotide sequence being specific for the C. perfringens sub-species inducing the targeted disease; and the second marker comprises a polynucleotide being specific for the species C. perfringens; and wherein an increase in the ratio of the first marker to the second marker in the analyzed sample material over time is an indication of the targeted disease.